3Derm is a previous MLSC awardee through the Center’s Accelerator Loan Program
3Derm Systems recently announced that it has been granted two FDA Breakthrough Device designations for 3DermSpot. The algorithm uses artificial intelligence (AI) and highly standardized skin images to autonomously detect melanoma, squamous cell carcinoma, and basal cell carcinoma.
3Derm is a previous MLSC awardee through the Center’s Accelerator Loan Program, designed to support early-stage companies through a critical stage of development and to leverage additional sources of capital to bring cutting-edge innovation to market.